Radicle ClarityTM 25_SR.1: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function

Launched by RADICLE SCIENCE · Jun 2, 2025

Keywords

ClinConnect Summary

The Radicle ClarityTM 25_SR.1 clinical trial is looking into how certain health and wellness products might improve cognitive function, which includes aspects like memory and thinking skills. This study will compare these products to a placebo, which is a fake treatment, to see if there are real benefits. If you're an adult aged 21 or older and live in the United States, you could be eligible to participate, as long as you're healthy enough to potentially see a 30% improvement in your cognitive function.

Participants will need to agree to take a product without knowing whether it's the active product or the placebo until the study is finished. It’s important to note that individuals who are pregnant, have certain health conditions, or are currently enrolled in another study won’t be able to join. If you decide to participate, you can expect to contribute to important research while being monitored for any changes in your cognitive abilities over the course of the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
• • Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
• • Resides in the United States
• • Has the opportunity for at least 30% improvement in their primary health outcome
• • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
• Exclusion Criteria:
• • Report being pregnant, trying to become pregnant, or breastfeeding
• • Unable to provide a valid US shipping address and mobile phone number
• • Reports current enrollment in another clinical trial
• • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• • Unable to read and understand English
• • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
• • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
• • NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
• • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
• • o Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
• • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products
• • Lack of reliable daily access to the internet